REalWorld insights on the INitiation and treatment Duration of ticagrEloR & other oral antiplatelets (OAP) in patients with Acute Coronary Syndrome (ACS) in Be/Lux. - REWINDER

Study identifier:NIS-CBE-XXX-2014/1

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

REalWorld insights on the INitiation and treatment Duration of ticagrEloR & other oral antiplatelets in patients with acute coronary syndrome in Belgium/Luxembourg (REWINDER)

Medical condition

Treatment of Acute Coronary Syndrome (ACS).

Phase

N/A

Healthy volunteers

No

Study drug

ACS patients treated with OAP

Sex

All

Actual Enrollment

430

Study type

Observational

Age

18 Years - 150 Years

Date

Study Start Date: 01 Sept 2014
Primary Completion Date: 01 Jan 2015
Study Completion Date: 01 Jan 2015

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria